NasdaqCM:XAIR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Beyond Air's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XAIR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

XAIR

4.4%

US Medical Equipment

1.6%

US Market


1 Year Return

28.9%

XAIR

6.1%

US Medical Equipment

4.8%

US Market

Return vs Industry: XAIR exceeded the US Medical Equipment industry which returned 6.1% over the past year.

Return vs Market: XAIR exceeded the US Market which returned 4.8% over the past year.


Shareholder returns

XAIRIndustryMarket
7 Day0%4.4%1.6%
30 Day0.4%-0.04%2.3%
90 Day-23.7%22.3%29.5%
1 Year28.9%28.9%7.0%6.1%7.1%4.8%
3 Yearn/a57.6%53.2%37.1%28.1%
5 Yearn/a107.6%91.4%67.2%48.6%

Price Volatility Vs. Market

How volatile is Beyond Air's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Beyond Air undervalued compared to its fair value and its price relative to the market?

6.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XAIR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: XAIR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XAIR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XAIR is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Beyond Air forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

63.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XAIR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: XAIR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XAIR's is expected to become profitable in the next 3 years.

Revenue vs Market: XAIR's revenue (59.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: XAIR's revenue (59.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Beyond Air performed over the past 5 years?

-26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XAIR is currently unprofitable.

Growing Profit Margin: XAIR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XAIR is unprofitable, and losses have increased over the past 5 years at a rate of -26.8% per year.

Accelerating Growth: Unable to compare XAIR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XAIR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).


Return on Equity

High ROE: XAIR has a negative Return on Equity (-110.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Beyond Air's financial position?


Financial Position Analysis

Short Term Liabilities: XAIR's short term assets ($26.7M) exceed its short term liabilities ($4.9M).

Long Term Liabilities: XAIR's short term assets ($26.7M) exceed its long term liabilities ($4.5M).


Debt to Equity History and Analysis

Debt Level: XAIR's debt to equity ratio (25.8%) is considered satisfactory.

Reducing Debt: XAIR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XAIR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XAIR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 24.9% each year.


Next Steps

Dividend

What is Beyond Air current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XAIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XAIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XAIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XAIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XAIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Steve Lisi (49yo)

3.08yrs

Tenure

US$1,268,835

Compensation

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD606.53K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Steven Lisi
CEO & Chairman of the Board3.08yrsUS$1.27m5.17% $6.2m
Amir Avniel
Co-Founder3.5yrsUS$819.72k2.86% $3.4m
Douglas Beck
Chief Financial Officer1.67yrsUS$406.25k0.092% $109.3k
Adam Newman
Chief Legal Officer & General Counsel2.33yrsUS$643.57kno data
Duncan Fatkin
Chief Commercial Officer1.5yrsUS$516.90k0.00059% $702.5
Asher Tal
Senior VP of Clinical Research & Member of Scientific Advisory Boardno datano datano data
Giora Davidai
Chief Medical Officer2.75yrsno datano data
Ali Ardakani
Senior Vice President of Device & Business Developmentno datano data0.17% $200.9k

2.8yrs

Average Tenure

49yo

Average Age

Experienced Management: XAIR's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Lisi
CEO & Chairman of the Board3.08yrsUS$1.27m5.17% $6.2m
Amir Avniel
Co-Founder3.5yrsUS$819.72k2.86% $3.4m
Asher Tal
Senior VP of Clinical Research & Member of Scientific Advisory Boardno datano datano data
Yoori Lee
Independent Director2.5yrsUS$97.25k0.043% $50.9k
Ron Bentsur
Independent Director3.5yrsUS$97.25kno data
Yossef Av-Gay
Member of Scientific Advisory Board2.5yrsUS$75.00kno data
Andrew Colin
Member of Scientific Advisory Boardno datano datano data
Erick Lucera
Independent Director2.92yrsUS$97.25k0.0069% $8.3k
Hugh O'Brodovich
Member of Scientific Advisory Boardno datano datano data
John Clancy
Member of Scientific Advisory Boardno datano datano data

3.0yrs

Average Tenure

50.5yo

Average Age

Experienced Board: XAIR's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XAIR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.2%.


Top Shareholders

Company Information

Beyond Air, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Beyond Air, Inc.
  • Ticker: XAIR
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$119.070m
  • Shares outstanding: 16.84m
  • Website: https://www.beyondair.net

Number of Employees


Location

  • Beyond Air, Inc.
  • 825 East Gate Boulevard
  • Suite 320
  • Garden City
  • New York
  • 11530
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XAIRNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2017
48LDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2017

Biography

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/03 00:22
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.